In the initial publication in 2021, the KETYNOTE-564 trial demonstrated that adjuvant pembrolizumab was associated with ...

During a Case-Based Roundtable® event, Julie R. Brahmer, MD, MSC, reviewed the CheckMate 9LA, KEYNOTE-407, and POSEIDON ...

The CRPC trial – KEYNOTE-921 – looked at the combination of Keytruda (pembrolizumab) with docetaxel in more than 1,000 patients who had not been treated with chemotherapy before, but who had ...

There were a number of debate-worthy outcomes from the KEYNOTE-062 trial that was presented at ASCO 2019 in Chicago yesterday. The study looked at Merck & Co's Keytruda as a first-line treatment ...

Health Canada has approved MSD's anti-programmed cell death protein 1 (PD-1) therapy Keytruda for treating adults with ...